Profile
Sector:
HealthcareIndustry:
Diagnostics & ResearchCountry:
United StatesIPO:
17 July 2014Website:
http://www.caredx.comNext earnings report:
02 August 2024Last dividends:
N/ANext dividends:
N/APrice
regular market | 8 min agoDividend
Analysts recommendations
Institutional Ownership
CDNA Latest News
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced in conjunction with the 2024 American Transplant Congress, the publication in Nature Medicine1 of findings from the largest, real-world study of its kind, assessing the role of AlloSure® donor-derived cell-free DNA (dd-cfDNA) and.
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today responded to Natera, Inc.'s filing of a motion for an injunction related to patent 11,111,544 (the ‘544 patent). The motion seeks to stop CareDx from using a prior AlloSure® process that Natera alleged infringed the ‘544 patent. That proces.
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA), The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that the Company will participate in two upcoming investor conferences. CareDx's management is scheduled to present at the: Jefferies Global Healthcare Conference on Thursday, June 6, 2023, at.
CareDx (CDNA) experienced a significant increase in its stock price in the previous session, with trading volume exceeding the usual levels. However, the recent changes in earnings estimates may not necessarily lead to a continued rise in the stock price in the short term.
CareDx (CDNA) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
CareDx, Inc. (CDNA) Q4 2023 Earnings Call Transcript
Beyond analysts' top -and-bottom-line estimates for CareDx (CDNA), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2023.
The average of price targets set by Wall Street analysts indicates a potential upside of 26.7% in CareDx (CDNA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
The mean of analysts' price targets for CareDx (CDNA) points to a 29.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
CareDx, Inc (NASDAQ:CDNA ) Q3 2023 Results Conference Call November 8, 2023 4:30 PM ET Company Participants Greg Chodaczek - Gilmartin Group, Managing Director Alex Johnson - President of Patient and Testing Services Abhishek Jain - Chief Financial Officer Robert Woodward - Chief Scientific Officer Michael Goldberg - Chairperson of the Board Conference Call Participants Andrew Cooper - Raymond James Alex Nowak - Craig-Hallum Capital Group Jacob Krahenbuhl - Stephens Dipesh Patel - H.C. Weinright Operator Good day, everyone, and welcome to today's CareDx Inc. Third Quarter 2023 Earnings Conference Call.
What type of business is CareDx?
CareDx, Inc. is a leading precision medicine company focused on discovering, developing, and commercializing clinically differentiated, high-value medical solutions for transplant patients and caregivers. CareDx, Inc. was founded in 1998 and is headquartered in South San Francisco, California. The company also develops, manufactures, and markets products that increase the likelihood of successful transplantation by facilitating matching between donor and recipient stem cells and organs. Key products of CareDx, Inc. include: - AlloSure Kidney - a cell-free DNA obtained from the donor (dd-cfDNA) solution for kidney transplant patients - AlloMap Heart - a gene expression solution for patients who have undergone heart transplantation.
What sector is CareDx in?
CareDx is in the Healthcare sector
What industry is CareDx in?
CareDx is in the Diagnostics & Research industry
What country is CareDx from?
CareDx is headquartered in United States
When did CareDx go public?
CareDx initial public offering (IPO) was on 17 July 2014
What is CareDx website?
https://www.caredx.com
Is CareDx in the S&P 500?
No, CareDx is not included in the S&P 500 index
Is CareDx in the NASDAQ 100?
No, CareDx is not included in the NASDAQ 100 index
Is CareDx in the Dow Jones?
No, CareDx is not included in the Dow Jones index
When does CareDx report earnings?
The next expected earnings date for CareDx is 02 August 2024